JOHNSON & JOHNSON - Q4 2020 holdings

 Value Shares↓ Weighting
No holdings reported for quarter Q4 2020
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LEGEND BIOTECH CORPORATION9Q3 202325.6%
FATE THERAPEUTICS, INC.9Q3 202324.8%
PROTAGONIST THERAPEUTICS INC.9Q3 202321.0%
CVRX, INC.9Q3 202319.5%
MEIRAGTX HOLDINGS PLC9Q3 202313.9%
Arrowhead Pharmaceuticals, Inc.9Q3 202324.6%
PROCEPT BIOROBOTICS CORPORATION9Q3 202310.5%
CUE HEALTH, INC.9Q3 20238.5%
FUSION PHARMACEUTICALS INC.9Q3 20235.4%
POINT BIOPHARMA GLOBAL INC.9Q3 20232.8%

View JOHNSON & JOHNSON's complete holdings history.

Latest significant ownerships (13-D/G)
JOHNSON & JOHNSON Q4 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Fusion Pharmaceuticals Inc.January 27, 20233,670,5168.2%
Protagonist Therapeutics, IncJanuary 11, 20232,449,1835.0%
MeiraGTx Holdings plcNovember 14, 20226,641,06413.7%
PhaseBio Pharmaceuticals IncFebruary 01, 20221,607,0443.3%
Provention Bio, Inc.January 17, 20201,124,9732.4%
ADURO BIOTECH, INC.January 22, 20193,906,2074.9%
Aldeyra Therapeutics, Inc.January 22, 20191,050,2924.0%
GI DYNAMICS, INC.January 22, 2019565,5693.7%
MACROGENICS INCJanuary 22, 20191,923,0774.6%
Merus N.V.January 22, 2019? ?

View JOHNSON & JOHNSON's complete significant-ownership history.

Latest filings
TypeFiled
8-K/A2024-04-16
8-K2024-04-16
32024-04-10
SC 13G2024-04-10
DFAN14A2024-04-05
PX14A6G2024-03-27
1442024-03-13
42024-03-13
ARS2024-03-13
DEF 14A2024-03-13

View JOHNSON & JOHNSON's complete filings history.

Compare quarters

Export JOHNSON & JOHNSON's holdings